Retreatment of hepatitis C non-responsive to Interferon: a placebo controlled randomised trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN53821378

Enrollment

117

Registered

2003-08-11

Start date

1992-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C Infections and Infestations Hepatitis

Interventions

Patients were randomised to: 1. 6 months combination therapy with interferon alpha-2b (3 MU tiw) and ribavirin (1000 - 1200 mg / day) 2. 6 months ribavirin monotherapy (1000 - 1200 mg / day) 3. 6 mont

Eligibility

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis C and elevated transaminases who did not respond to previous treatment with standard interferon monotherapy.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026